01.01.13
Nestlé Health Science, a fully owned subsidiary of Nestlé, and the pharmaceutical and healthcare group Chi-Med have agreed to form a 50/50 joint venture to be named Nutrition Science Partners Limited (NSP), which will research, develop, manufacture and market innovative nutritional and medicinal products derived from botanical plants. Focus will be on gastrointestinal health and may in the future expand into the metabolic disease and brain health areas.
The partnership gives Nestlé Health Science access to Chi-Med’s Traditional Chinese Medicine (TCM) library of more than 50,000 extracts from more than 1,200 different herbal plants, and includes access to the botanical research and development platform in gastrointestinal areas, which includes discovery research, non-clinical and pharmaceutical science functions and an understanding of the botanical guidelines and regulations.
Hutchison MediPharma Limited, a subsidiary of Chi-Med, has already made advancements in the research and development of a first-of-its-kind botanical product, to be taken orally, to manage mild to moderate inflammatory bowel disease. Its main ingredient is extracted from Andrographis paniculata, an herb used in TCM. The new partnership will further support product development during its next stage of clinical trials, which is scheduled to start in early 2013.
The partnership gives Nestlé Health Science access to Chi-Med’s Traditional Chinese Medicine (TCM) library of more than 50,000 extracts from more than 1,200 different herbal plants, and includes access to the botanical research and development platform in gastrointestinal areas, which includes discovery research, non-clinical and pharmaceutical science functions and an understanding of the botanical guidelines and regulations.
Hutchison MediPharma Limited, a subsidiary of Chi-Med, has already made advancements in the research and development of a first-of-its-kind botanical product, to be taken orally, to manage mild to moderate inflammatory bowel disease. Its main ingredient is extracted from Andrographis paniculata, an herb used in TCM. The new partnership will further support product development during its next stage of clinical trials, which is scheduled to start in early 2013.